Peme-Sol 25 mg/ml

/ Teva Israel LTD, Israel

The generally accepted dosage is 500 mg for every square meter of the body surface area (BSA), administered as an intravenous infusion over 10 minutes.
When combined with Cisplatin, after finishing pemetrexed infusion, wait about 30 minutes and wash the infusion tube before giving Cisplatin.
Please refer to the license holder for further details.

This medicinal product in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery.
This medicinal product in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
This medicinal product is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
This medicinal product is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Hypersensitivity to the active substance or to any of the excipients.
Breast-feeding.
Concomitant yellow fever vaccine.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Store in the fridge (2°C to 8°C), in the original package in order to protect from light. Do not freeze.